http://www.ncbi.nlm.nih.gov/pubmed/10750566
Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis.
Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis.
These findings suggest that vitamin K2 treatment effectively prevents the occurrence of new fractures, although the vitamin K2-treated group failed to increase in LBMD.
Estudo avaliando o efeito da k2 na prevenção de
fraturas em virtude da osteoporose:
Os resultados sugerem que o tratamento com a
vitamina k2 previne efetivamente a ocorrência de novas fraturas, embora o grupo
tratado com a vitamina k-2 não tenha tido ganhos no aumento da densidade
mineral óssea lombar.
Abstract
We
attempted to investigate whether vitamin K2 (menatetrenone) treatment
effectively prevents the incidence of new fractures in osteoporosis.
A
total of 241 osteoporotic patients were enrolled in a 24-month randomized open
label study.
The
control group (without treatment; n = 121) and the vitamin K2-treated group (n
= 120), which received 45 mg/day orally vitamin K2, were followed for lumbar
bone mineral density (LBMD; measured by dual-energy X-ray absorptiometry [DXA])
and occurrence of new clinical fractures.
Serum
level of Glu-osteocalcin (Glu-OC) and menaquinone-4 levels were measured at the
end of the follow-up period.
Serum
level of OC and urinary excretion of deoxypyridinoline (DPD) were measured
before and after the treatment.
The
background data of these two groups were identical. The incidence of clinical
fractures during the 2 years of treatment in the control was higher than the
vitamin K2-treated group (chi2 = 10.935; p = 0.0273).
The
percentages of change from the initial value of LBMD at 6, 12, and 24 months
after the initiation of the study were -1.8 +/- 0.6%, -2.4 +/- 0.7%, and -3.3
+/- 0.8% for the control group, and 1.4 +/- 0.7%, -0.1 +/- 0.6%, and -0.5 +/-
1.0% for the vitamin K2-treated group, respectively. The changes in LBMD at
each time point were significantly different between the control and the
treated group (p = 0.0010 for 6 months, p = 0.0153 for 12 months, and p =
0.0339 for 24 months).
The
serum levels of Glu-OC at the end of the observation period in the control and
the treated group were 3.0 +/- 0.3 ng/ml and 1.6 +/- 0.1 ng/ml, respectively (p
< 0.0001), while the serum level of OC measured by the conventional
radioimmunoassay (RIA) showed a significant rise (42.4 +/-6.9% from the basal
value) in the treated group at 24 months (18.2 +/- 6.1% for the controls;p =
0.0081).
There
was no significant change in urinary DPD excretion in the treated group.
These
findings suggest that vitamin K2 treatment effectively prevents the occurrence
of new fractures, although the vitamin K2-treated group failed to increase in
LBMD.
Furthermore, vitamin K2 treatment enhances gamma-carboxylation of the OC
molecule
Nenhum comentário:
Postar um comentário